Compare Stocks → Incredible Opportunity to Retire FAST! (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:GERNNYSE:LCINASDAQ:NERVNASDAQ:OPTNNASDAQ:PTGX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGERNGeron$3.73+1.1%$2.77$1.64▼$4.05$2.04B0.6111.20 million shs8.21 million shsLCILannett$1.54$0.64▼$3.72$7.38M0.9592,067 shs280,600 shsNERVMinerva Neurosciences$2.55+2.8%$3.77$2.26▼$13.49$17.82M0.21104,880 shs10,036 shsOPTNOptiNose$1.03+15.7%$1.49$0.86▼$2.10$116.03M-0.24545,861 shs1.26 million shsPTGXProtagonist Therapeutics$26.61+3.9%$28.49$13.72▼$33.34$1.55B2.02705,845 shs296,277 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGERNGeron+1.08%+8.12%+12.69%+75.12%+39.70%LCILannett0.00%0.00%0.00%0.00%0.00%NERVMinerva Neurosciences+2.82%+5.37%-4.49%-67.10%+3.66%OPTNOptiNose+15.19%-13.45%-36.81%-27.46%-44.92%PTGXProtagonist Therapeutics+3.90%+0.11%-5.07%+6.53%+10.78%The A.I. story nobody is telling you (Read ASAP) (Ad)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGERNGeron3.3911 of 5 stars3.53.00.01.32.01.70.6LCILannettN/AN/AN/AN/AN/AN/AN/AN/ANERVMinerva Neurosciences3.0517 of 5 stars3.03.00.04.61.70.00.0OPTNOptiNose3.1167 of 5 stars3.53.00.04.20.02.50.6PTGXProtagonist Therapeutics1.7181 of 5 stars3.51.00.00.03.22.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGERNGeron3.00Buy$5.3342.98% UpsideLCILannettN/AN/AN/AN/ANERVMinerva Neurosciences2.00Hold$11.00331.37% UpsideOPTNOptiNose3.00Buy$4.00288.35% UpsidePTGXProtagonist Therapeutics3.00Buy$36.0035.29% UpsideCurrent Analyst RatingsLatest LCI, GERN, NERV, PTGX, and OPTN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/10/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.003/18/2024OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/18/2024OPTNOptiNoseLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$3.00 ➝ $4.003/15/2024GERNGeronWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$6.003/15/2024GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.003/15/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.003/11/2024OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$5.002/28/2024GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.002/28/2024PTGXProtagonist TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$34.00 ➝ $37.002/28/2024PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGERNGeron$240K8,499.27N/AN/A$0.46 per share8.11LCILannett$340.58M0.00N/AN/A($23.34) per share0.00NERVMinerva NeurosciencesN/AN/AN/AN/A($4.07) per shareN/AOPTNOptiNose$70.99M1.63N/AN/A($0.77) per share-1.34PTGXProtagonist Therapeutics$60M25.85N/AN/A$5.84 per share4.56Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGERNGeron-$184.13M-$0.33N/AN/AN/A-77,691.14%-63.33%-44.71%5/9/2024 (Estimated)LCILannett-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/ANERVMinerva Neurosciences-$30M-$4.65N/AN/AN/AN/AN/A-50.27%5/20/2024 (Estimated)OPTNOptiNose-$35.48M-$0.32N/AN/AN/A-50.06%N/A-33.05%5/9/2024 (Estimated)PTGXProtagonist Therapeutics-$78.96M-$1.49N/AN/AN/AN/A-27.49%-25.30%5/2/2024 (Estimated)Latest LCI, GERN, NERV, PTGX, and OPTN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/202412/31/2023OPTNOptiNose-$0.10-$0.09+$0.01-$0.09$19.90 million$19.87 million 2/28/2024Q4 23GERNGeron-$0.10-$0.09+$0.01-$0.09$0.06 million$0.02 million 2/27/202412/31/2023PTGXProtagonist Therapeutics$0.05$0.44+$0.39$0.44$60.00 million$60.00 million2/22/2024Q4 2023NERVMinerva Neurosciences-$0.88-$1.19-$0.31-$1.19N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGERNGeronN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/AOPTNOptiNoseN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGERNGeron0.143.163.16LCILannettN/A2.231.39NERVMinerva NeurosciencesN/A12.5712.58OPTNOptiNoseN/A0.600.55PTGXProtagonist TherapeuticsN/A16.7116.71OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGERNGeron73.71%LCILannett40.28%NERVMinerva Neurosciences34.56%OPTNOptiNose85.60%PTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipGERNGeron3.00%LCILannett13.12%NERVMinerva Neurosciences6.40%OPTNOptiNose2.20%PTGXProtagonist Therapeutics5.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableGERNGeron141546.87 million530.47 millionOptionableLCILannett81010.77 million9.35 millionOptionableNERVMinerva Neurosciences96.99 million6.55 millionNot OptionableOPTNOptiNose132112.65 million110.17 millionNot OptionablePTGXProtagonist Therapeutics11258.28 million55.36 millionOptionableLCI, GERN, NERV, PTGX, and OPTN HeadlinesSourceHeadlineProtagonist Pictures boards Cannes Directors’ Fortnight title ‘Sister Midnight’; unveils first look (exclusive)screendaily.com - April 22 at 5:04 PMAsif Ali Sells 1,234 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stockamericanbankingnews.com - April 21 at 6:24 AMProtagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali Sells 1,234 Sharesinsidertrades.com - April 20 at 7:28 AMInsider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Sells 1,234 Shares of Stockmarketbeat.com - April 20 at 12:23 AMReadystate Asset Management LP Has $1.31 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - April 18 at 9:37 PMProtagonist Therapeutics (NASDAQ:PTGX) Stock Price Passes Below 50-Day Moving Average of $28.56americanbankingnews.com - April 18 at 4:26 AMVanguard Group Inc. Raises Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)marketbeat.com - April 9 at 4:08 AMAll You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buyzacks.com - April 5 at 1:01 PMProtagonist Pictures’ Len Rowles to join development fund Climate Spring (exclusive)screendaily.com - April 3 at 8:30 AMInsider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells 25,000 Shares of Stockinsidertrades.com - April 3 at 4:58 AMProtagonist Therapeutics Inc CEO Sells 25,000 Sharesfinance.yahoo.com - April 3 at 3:29 AMShareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135%finance.yahoo.com - April 1 at 4:10 PMProtagonist Therapeutics Earns ‘Buy’ Rating on Strong Clinical Progress and Strategic Partnershipsmarkets.businessinsider.com - March 27 at 11:05 AMProtagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Dataaccesswire.com - March 26 at 7:00 AMWall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Betzacks.com - March 18 at 10:56 AMProtagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takedafinanznachrichten.de - March 18 at 9:09 AMPTGX Apr 2024 15.000 callfinance.yahoo.com - March 15 at 11:37 PMPTGX Apr 2024 30.000 putfinance.yahoo.com - March 15 at 11:37 PM4 Stocks to Buy for Attractive Earnings Accelerationzacks.com - March 15 at 7:16 AMThe People's Market owner snaps up former Protagonist space in heart of NoDa for barbizjournals.com - March 12 at 4:15 PMBuy Rating Affirmed for Protagonist Therapeutics on Strong Phase 2b Results and Strategic Phase 3 Dosing of JNJ-2113markets.businessinsider.com - March 12 at 12:49 AMStrong Buy Rating for Protagonist Therapeutics on JNJ-2113’s Promising Psoriasis Treatment Efficacy and Financial Outlookmarkets.businessinsider.com - March 11 at 8:33 AMProtagonist Therapeutics to Participate in Upcoming Investor Conferencesaccesswire.com - March 6 at 4:05 PM4 Must-Buy Stocks for Remarkable Earnings Accelerationzacks.com - March 4 at 8:06 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsGeronNASDAQ:GERNGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.LannettNYSE:LCILannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.Minerva NeurosciencesNASDAQ:NERVMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.OptiNoseNASDAQ:OPTNOptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.Protagonist TherapeuticsNASDAQ:PTGXProtagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.